Walking the walk, Alnylam appoints former FDA head Margaret Hamburg to the board
Right on the heels of an industry-wide notice from BIO to speed up gender diversity in the C-suite and boardroom, Alnylam is adding to its roster with the appointment of former FDA commissioner Margaret Hamburg to the board.
The letter, prompted by a slate of controversies over the lack of gender diversity and inclusion during high-level conferences such as JPM and BIO, was signed off by Alnylam CEO John Maraganore, this year’s chairman, along with Halozyme chief Helen Torley and BIO chief Jim Greenwood.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.